Furthermore, dual ICB, which targets both PD-1 and CTLA-4 at the same time, has shown greater efficacy than single ICB in patients with metastatic NSCLC and melanoma (40, 43), and is more effective in melanoma patients with smaller baseline tumor diameters (50). The gene discussed is CTLA4; the disease is melanoma.